Shamburg News · 8-K filed Oct 9, 2026, 7:59 AM EDT

Quince Therapeutics Renames to IRulya Therapeutics; Names New CEO, CFO and COO

IRLA · Quince Therapeutics, Inc.

  • Leadership change
  • Shareholder vote
  • Other event
  • Material agreement
  • Reg FD disclosure
  • Materiality: high

Quince Therapeutics, Inc. announced that its Chief Executive Officer Dirk Thye, M.D., and Chief Operating Officer Brendan Hannah resigned effective October 8, 2026, and that Brigette Roberts, M.D., was appointed Chief Executive Officer, John Militello, CPA, as Chief Financial Officer, and Keith Fandrick, Ph.D., as Chief Operating Officer. Four new directors were appointed and Thye and three other directors resigned from the Board effective October 8, 2026. The Company filed an amendment to change its name to IRulya Therapeutics Inc., effective 4:01 p.m. Eastern Time on October 9, 2026, with common stock to trade on the Nasdaq Capital Market under the symbol IRLA beginning October 12, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 5.03, 7.01, 8.01, 9.01, accession 0001193125-26-418538.

Written from the filing by Shamburg Markets. Figures are as reported by the company.